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Fatty liver disease is a common lipid metabolism disorder inﬂuenced by the combination of individual genetic makeup, drug
exposure, and life-style choices that are frequently associated with metabolic syndrome, which encompasses obesity, dyslipidemia,
hypertension,hypertriglyceridemia, andinsulinresistantdiabetes. Commontoobesityrelateddyslipidemiaistheexcessive storage
of hepatic fatty acids (steatosis), due to a decrease in mitochondria β-oxidation with an increase in both peroxisomal β-oxidation,
and microsomal ω-oxidation of fatty acids through peroxisome proliferator activated receptors (PPARs). How steatosis increases
PPARα activated gene expression of fatty acid transport proteins, peroxisomal and mitochondrial fatty acid β-oxidation and ω-
oxidation of fatty acids genes regardless of whether dietary fatty acids are polyunsaturated (PUFA), monounsaturated (MUFA),
or saturated (SFA) may be determined by the interplay of PPARs and HNF4α with the fatty acid transport proteins L-FABP and
ACBP. In hepatic steatosis and steatohepatitis, the ω-oxidation cytochrome P450 CYP4A gene expression is increased even with
reduced hepatic levels of PPARα. Although numerous studies have suggested the role ethanol-inducible CYP2E1 in contributing to
increased oxidative stress, Cyp2e1-null mice still develop steatohepatitis with a dramatic increase in CYP4A gene expression. This
strongly implies that CYP4A fatty acid ω-hydroxylase P450s may play an important role in the development of steatohepatitis. In
this review and tutorial, we brieﬂy describe how fatty acids are partitioned by fatty acid transport proteins to either anabolic or
catabolic pathways regulated by PPARs, and we explore how medium-chain fatty acid (MCFA) CYP4A and long-chain fatty acid
(LCFA) CYP4F ω-hydroxylase genes are regulated in fatty liver. We ﬁnally propose a hypothesis that increased CYP4A expression
with a decrease in CYP4F genes may promote the progression of steatosis to steatohepatitis.
Copyright © 2009 James P. Hardwick et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Disorders of lipid metabolism are closely dependent on
genetic factors, exposure to drugs, and many common life-
style choices (e.g., diets and alcohol) that often lead to
metabolic syndrome in which patients exhibit obesity, dys-
lipidemia, hypertension, hypertriglyceridemia, and insulin
resistance diabetes [1, 2]. Common to obesity-related dys-
lipidemia and hypertriglyceridemia is the excessive storage
of fatty acids in the liver (steatosis) frequently referred as
nonalcoholic fatty liver disease (NAFLD). Increased hepatic
fatty acids can cause lipotoxicity and initiate fatty liver
inﬂammation (steatohepatitis) commonly referred as nonal-
coholic steatohepatitis (NASH) [3]. Excessive fatty acids in2 PPAR Research
the liver dramatically alter lipid metabolism by decreasing
mitochondrial β-oxidation, while increasing peroxisomal
β-oxidation and microsomal ω-oxidation of fatty acids
resulting in lipotoxicity [4, 5]. During hepatic steatosis,
members of CYP4 family of fatty acid ω-hydroxylase are
induced even with the downregulation of PPARα,w h i c h
regulates CYP4A gene expression. Numerous reports have
indicated that the ethanol-inducible CYP2E1 is induced in
both hepatic steatosis and steatohepatitis [6, 7] even though
Cyp2e1-null mice develop steatohepatitis with a markedly
increased CYP4A gene expression, suggesting that CYP4A
P450 may also play an important role in the progression
of NAFLD to NASH. Since elevated levels of long chain
fatty acids (LCFAs) and LCFA coenzyme A esters (LCFA-
CoAs)areobservedinhepatic steatosisandseveralmetabolic
disorders, including obesity, diabetes and hyperlipidemia,
it is of necessity that we understand the mechanism that
regulates fatty acid (FA) transport and partitioning of free
fatty acids (FFA) and fatty acid-CoA in the initiation of fatty
liver lipotoxicity in the progression of NAFLD to NASH.
Intracellular fatty acids (FAs) and their metabolites
coordinate physiological processes by several transcriptional
factors controlling energy metabolism. For instance, several
transcriptional factors include: peroxisome proliferator acti-
vated receptors (PPARα,P P A R δ,P P A R γ), sterol regulatory
binding proteins (SREBP-1 and SREBP-2), liver X receptor
(LXRα), and carbohydrate response element binding protein
(ChREBP),allofwhichareactivatedorrepressedbydiﬀerent
fatty acids [8]. Both polyunsaturated fatty acids (PUFAs)
eicosapentaenoicacid(EPA,C20:5n-3) and docosahexaenoic
acid (DHA, C22:6n-3) and LCFA-CoA bind and activate
PPARα to increase fatty acid oxidation, gluconeogenesis, and
ketogenesis [9] ,w h i l eP U F A ss u p p r e s sa c t i v a t i o no fS R E B P -
1c, ChREBP, and LXRα through diverse mechanisms [10].
In contrast, saturated fatty acids activate HNF4α through
binding to acyl-CoA binding protein (ACBP) containing
LCFA while SREBP-1c activation by LCFA occurs by recruit-
ing SREBP-1c and PPARγ coactivator-1β (PGC-1β). In
addition, intracellular fatty acids produced from triglyceride
hydrolysis or de novo lipogenesis (DNL) can regulate gene
expression, suggesting that not only the type of fatty acids
(saturated versus unsaturated), sources (intracellular versus
exogenous), fatty acid association with diﬀerent fatty acid
transport proteins (L-FABP and ACBP), and type of fatty
acid metabolites (FATP/ACSVL) have selective eﬀects in
regulating genes involved in oxidation, synthesis, and storage
of fatty acids [10, 11]. Perturbations in these pathways by
nutritions, drugs, alcohol, or genetic factors lead to fatty acid
disorders often associated with dyslipidemia, obesity, and
diabetes [12–14].
2. Causesof HepaticSteatosis inNAFLD
Convincing evidence has shown that fatty liver is closely
associated with insulin resistance and metabolic syndrome.
Although, life style choices of a high carbohydrate or
a high fat diet and excessive alcohol consumption are
speciﬁc causes of hepatic steatosis and NAFLD, nutritional
factors (e.g., malnutrition and rapid weight loss) [15], drug
exposure (e.g., glucocorticoids, methotrexate, Amiodarone,
Tamoxifen, HIV protease inhibitors, etc.) [12, 16], speciﬁc
diseases (e.g., inﬂammatory bowel disease, primary biliary
cirrhosis, Cushing’s syndrome, Hematochromatosis, etc.),
and genetic factors [17] are also relevant causes of fatty liver
diseases [16, 18–22].
Themajorsourcesoffattyacidsthatcontributetohepatic
steatosis include fat stored in adipose tissues and released
during fasting by lipolysis to increase plasma levels of
nonesteriﬁed fatty acid (NEFA), which provides the majority
of fatty acids secreted by liver as VLDL. During adipose
insulin resistance, the increased release of fatty acids leads
to elevated accumulation of TAG in fatty liver. A second
source of increased plasma NEFA is through liver de novo
lipogenesis (DNL) while dietary fatty acid, from intestinal-
derived chylomicron remnants, also increases the plasma
pool of NEFAs. In patients with NAFLD, 59% of TAG fatty
acid is derived from adipose lipolysis while 26% is from DNL
and 15% from the dietary NEFA pool [21]. The elevated
DNL in patients with NAFLD compared to patients without
NAFLD does not change after a meal. In contrast, in normal
control individuals it increases from 5% to 28% 4 hours
after a meal [22] .I nN A F L D ,t h eN E F Ap o o lc o n t r i b u t e s
equally to the liver TAG and VLDL TAG even though
NAFLD patients have a reduced ability to increase VLDL
production during fasting, suggesting that NAFLD patients
have a limited capacity to adapt to metabolic changes that
occur during cycles of fasting and feeding [23].
Thus, plasma NEFAs from adipose stores or dietary
sources provide most of the hepatic lipid in NAFLD.
Therefore, the regulatory mechanism of fatty acid uptake
by hepatocytes and cellular distribution of esteriﬁed and
nonesteriﬁed fatty acids have an important role in the
initiation of hepatic steatosis in NAFLD. There are ﬁve
mechanisms responsible for fatty acid uptake that initiates of
fattyliver.Facilitatedtransportistheprimarymechanismfor
the uptake of free fatty acids (FFAs) into hepatocytes under
normal plasma NEFA levels (225–700uM). However, higher
plasma NEFA concentrations may overload this saturable
system, resulting in the activation of a passive nonsaturable
pathway to reduce plasma NEFA levels, unfortunately with
the consequence of hepatic steatosis [24]. The saturable
systems for plasma membrane fatty acid transport are
caveolins, fatty acid transport proteins (FATPs), fatty acid
translocase (FAT/CD36), and fatty acid binding proteins
(FABPs). Caveolin-1 of lipid rafts is localized within plasma
membrane invaginations that have a critical role in cell
signaling, protein traﬃcking, and uptake of fatty acids;
caveolin-1 deﬁcient mice are resistant to diet induced obesity
[25]. FATPs are a family of six integral membrane proteins
with an extracellular/luminal N-terminal and C-terminal
domain with fatty acyl-CoA synthetase activity and therefore
FATP proteins have the ability to trap FA intracellularly [26]
(Table 1). FATP2 (ACSVL1), FATP5 (ASCLV6), and FATP4
(ACSVL5) are expressed in the liver and are regulated by
PPARα and PPARγ [27]. Both FATP2 and FATP4 have a
strong substrate preference in transport and activation of
C16:0 to C24:0 straight chain and branched-chain fattyPPAR Research 3
acids while FATP5 (ACSVL6) preferentially transports and
activates bile acids [26]. FATP5 knockout mice show a 50%
decrease in hepatocyte fatty acid uptake with reduced caloric
uptake, and improved whole body glucose homeostasis.
Consequently, these mice were protected from high fat
induced hepatic steatosis [28]. FATP5 also exhibits bile acid
CoA synthetase activity and therefore Fatp5-null mice display
a dramatic increase in unconjugated bile acids. As expected
Fatp5-null mice are resistant to obesity and hepatic accu-
mulation of TAG with improved insulin sensitivity [28, 29].
In adenovirus FATP4 infected rat hepatocytes, there was a
30% increase in fatty acid uptake and 2-fold increase in acyl-
CoAactivitywitha42%increaseinTAGsynthesis,indicating
that FATP4 partitions fatty acids towards TAG synthesis and
storage [30–32]. In human hepatocytes, FATP4 knockdown
decreased C18:1 incorporation into phospholipids and VLDL
synthesis, suggesting an anabolic role of FATP4 in energy
metabolism [33]. In contrast, overexpression of FATP2 in
primary hepatocytes results in C18:1 channeling toward
diacylglycerol and phospholipid synthesis with shift away
from cholesterol esteriﬁcation [33]. FATP2 is regulated by
PPARα agonists as well as high carbohydrate and high fat
diets which increase FATP2 expression 8-fold in rat liver.
However, surprisingly the PPARγ ligand BRL-49953 induces
FATP2 expression in adipose tissue, which is similar with
insulin induced FATP2 expression [34]. It is therefore not
surprising that FATP2 is induced in obese Zucker (fa/fa)
rats and that both FATP2 and FATP4 mRNA are increased
in hepatocytes by carbohydrates feeding and by insulin
through SREBP-1c [35]. FAT/CD36 is expressed in a broad
range of tissues and cell types. It promotes fatty acid release
from albumin and insertion into the plasma membrane by
facilitated diﬀusion with the assistance of L-FABP. Although
expression of CD36/FAT is low in hepatocytes, this transport
protein is unique since it mediates the uptake of VLCL and
oxidized LDL. Cd36-null mice show a higher level of plasma
NEFA,higher liverTAG, andsevere hepatic insulin resistance
[36]. The induction of CD36/FAT in mice fed a high fat
diet results in fatty liver [37], and patients with increased
expression of this protein have a higher level of hepatic
fatty acids and display NAFLD [38]. CD36/FAT expression
is controlled by the pregnane X receptor (PXR), PPARγ,a n d
the LXRα [37].
FABPandACBPbindadiversearrayoffattyacidsinclud-
ing eicosanoids [39] and facilitate intracellular transport of
FA and FA-CoAs from the cytosol to diﬀerent organelles
including the nucleus. Unlike FATP, this protein does not
exhibit acyl-CoA synthetase activity (Table 1). There are nine
diﬀerent FABPs each of which shows distinct tissue speciﬁc
distribution with L-FABP being prominently expressed in
the liver. L-Fabp-null mice show a 2-fold increase in hepatic
TAG compared to a 10-fold increase in wild type mice after
a 48-hour fasting, which was due to decreased TAG secretion
and reduced fatty acid oxidation [40]. L-Fabp-null mice fed
a high fat western diet are resistant to diet induced obesity
and show a similar increase in TAG secretion as the wild type
mice [41], suggesting either that other fatty acid transport
proteins compensate for L-FABP or increased plasma NEFAs
initiate passive diﬀusion. A high fat diet potently increases
the expression of L-FABP [42] and microsomal triglyceride
transfer protein (MTP) via PPARα, thereby leading to eﬃ-
cient delivery of FA for VLDL assembly and secretion [43].
In contrast, the repression of these enzymes would reduce
VLDL secretion without causing TAG accumulation in the
liver[44].ACBP,responsiblefortransportingacyl-CoAesters
intracellularly, is downregulated during fasting but induced
by insulin through SREBP-1c, and ﬁbrates through PPARα
[45]. Thus ACBP is a dual PPARα and SREBP-1c target gene
where fasting reduces SREBP-1c expression and increases
PPARα in hepatocytes, thus reﬂecting a dual role of ABCP
in lipogenesis and lipid oxidation.
The apparently similar mechanism that regulates FATP2,
FATP4, ACBP, and L-FABP by PPARα during fasting induced
fatty acid inﬂux with the paradoxical upregulation by insulin
through SREBP-1c identiﬁes an ideal mechanism to prevent
lipotoxicity [46]. Cellular acyl-CoA levels correlate with
hepaticinsulinresistanceandhavebeensuggestedtomediate
lipotoxicity. Because the normal acyl-CoA levels in cytosol
are between 1 and 20uM, and ACBP and FABP comprise up
to5%ofthetotalhepaticcytosolproteins[34],itislikelythat
most acyl-CoAs are bound to ACBP and/or FABP and thus
FFAs may be the major culprit in causing lipotoxicity. Since
LCFA-CoA production is controlled by FATPs, which chan-
nel acyl-CoAs to the synthesis of phospholipids, cholesterol
esters, and triglycerides or oxidation by the mitochondrial
and peroxisomal β-oxidation pathways or microsomal ω-
oxidation, it is highly likely that elevated NEFAs in serum
during fasting and hepatic steatosis signiﬁcantly increase the
intracellular pool of unesteriﬁed fatty acids in hepatocytes.
The increased synthesis of TAG observed in hepatic steatosis
may be a compensatory mechanism to reduce intracellular
FFAs and lipotoxicity. Therefore, the upregulated FATP2,
FATP4 and FATP5 expression in obese rats increases TAG
synthesis and storage, while increased FATP expression pro-
motes the cellular importation of FFAs [33, 47], leading to
FFAoverloadandhepaticsteatosis.However,theknockdown
of FATP3 (ACSLV3) in primary rat hepatocytes revealed a
signiﬁcant reduction in the expression of several lipogenic
transcriptionfactors,PPARγ,ChREBP,SREBP-1c,andLXRα
as well as their target genes [46, 48].
Since the knockdown (or knockout) of diﬀerent FATP
isoforms reduces hepatic steatosis and in some cases
increasesinsulinsensitivityandglucosehandling,itisimper-
ative that we understand the mechanism through which
various FATP isoforms interact with diﬀerent metabolic
enzymes and/or intracellular transport proteins (L-FABP
and ACBP) to regulate lipogenesis, TG synthesis and storage,
and fatty acid oxidation pathways. These mechanistic studies
will provide valuable insights into how hepatic steatosis
causes lipotoxicity and the progression of steatosis to steato-
hepatitis.
3. Role of PPAR inthe Regulation of
Fatty Acid Metabolic Fate
Theoverexpressionofvariousfattyacidtransportproteinsin
diﬀerent cell lines, and their ability to channel FA to diﬀerent4 PPAR Research
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metabolic fates within the cell [49] may be determined by
the energy demands of speciﬁc metabolic pathways. Indeed,
FATP proteins are not only associated with the plasma mem-
brane but are also present in speciﬁc organelles (Table 1).
FATP5 is intimately associated with the mitochondria while
FATP2 (ACSVL1) is localized in peroxisomes. CD36/FAT
is closely correlated with the degree of mitochondrial fatty
acid oxidation, while L-FABP, also known as the mito-
chondrial aspartate aminotransferase (mAST), may have
distinct functions at diﬀerent subcellular sites. Unlike FATP
which activates FA to FA-CoA, FABP proteins transport
fatty acids to diﬀerent intracellular compartments. The
association of FATP with diﬀerent subcellular organelles may
also function in preventing lipotoxicity through increased
metabolism. This mechanism may be important in hepatic
fattyacidpartitioningtodiﬀerentmetabolicpathwaysduring
hepatic steatosis. Recent studies have shown that L-FABP
also functions to shuttle lipids to the nucleus to allow
them to directly interact with PPARα [49], suggesting an
important role of L-FABP in controlling the metabolism
of LCFAs. The ability of fatty acids to regulate metabolic
pathways through activation of nuclear receptors has long
been known; however the observation that L-FABP assists
in supplying lipid ligands for nuclear receptors suggests an
important feedback regulatory mechanism of L-FABP and
FAs in controlling lipid metabolism.
The ability of FATPs to target fatty acids to speciﬁc
cellular organelles for either fatty acid oxidation or synthesis
and their ability to direct fatty acid ligands to activate
selective nuclear receptors represent an eﬃcient mechanism
to control both metabolic pathways at the transcriptional
and substrate levels. The activation of hepatocyte nuclear
factor4α(HNF4α)andPP ARαthatbindsimilardirectrepeat
DNA elements (DR1) by diﬀerent fatty acids suggests an
eﬃcientmechanismtocontrolgloballyfattyacidmetabolism
[50, 51]( Figure 1). It has been shown that saturated LCFA
and VLCFA are extremely poor or nonactivators of PPARα.
Therefore it was uncertain how increased hepatic fatty acids
during fasting would increase PPARα target genes involved
infattyacidβ-oxidation,VLDLproduction,andketogenesis.
This was resolved by demonstration that LCFA-CoA and
VLCF-CoA are high aﬃnity PPARα ligands. PPARα has a
high aﬃnity for polyunsaturated fatty acids (PUFAs) and
LCFA-CoA, while these saturated LCFAs or VLCFAs are non-
selective in the activation of PPARα,P P A R δ,a n dP P A R γ.I n
vivo, the importance of acyl-CoA in the activation of PPARα
target genes was apparent when it was found that CoA esters
ofperoxisomeproliferatorchemicalsordrugswereactivating
ligands for PPARα mediated expression of peroxisomal
fatty acid β-oxidation genes, Acyl-CoA oxidase (AOX1),
bifunctional protein and thioesterase [52–54]. It was also
found that peroxisome proliferator-CoA esters (PP-CoAs)
are potent inhibitors of HNF4α activation. The importance
of VLCFA-CoAs in activation of PPARα was shown in
the in vivo animal model of Aox1-null mice, which show
elevatedplasmalevelsofVLCFAsandincreasedhepaticlevels
of VLCFA-CoAs. The inability of peroxisomal β-oxidation
systemtometabolizeVLCFA-CoAsresultsinhyperactivation
of PPARα and increased expression of target genes [55]. In
contrast, HNF4α has a high aﬃnity for saturated LCFAs,
and VLCFAs, but not PUFA-CoAs or LCFA-CoAs, suggesting
that fatty acid CoA, chain length, and degree of unsaturation
determine whether HNF4α or PPARα will be activated
and therefore which metabolic pathway controlled by these
nuclear receptors [10, 56]. Thus, the elevated uptake and
transport of LCFA-CoAs or PUFAs to the nucleus by L-
FABP activate PPARα and increase fatty acid oxidation. In
contrast, ACBP binds saturated LCFAs, which preferentially
bind and activate HNF4α. Therefore, PPARα/L-FABP and
HNF4α/ACBP would mediate a diﬀerential association with
coactivators and corepressors to their respective target genes
to control fatty metabolism. This suggests that binding of
saturated LCFAs to ACBP and its association with HNF4α
would increase HNF4α transcription activity and inhibit
PPARα, while transactivation of PPARα with PUFAs or
LCFA-CoAs would decrease HNF4α activation [10]. Thus, in
hepatic steatosis, the ratio of saturated to unsaturated fatty
acids with increased expression of selective fatty acid trans-
port proteins (FATP/L-FABP/ACBP) may mediate metabolic
defects accounting for hepatic steatosis. Consequently, LCFA
activation of HNF4α with ACBP would increase plasma
levels of lipid rich lipoproteins (VLDL, LDL, and HDL)
and their constituent apolipoproteins (AI, AII, B, and CIII).
In contrast, dietary PUFAs associated with L-FABP would
activate PPARα, resulting in decreased transcription of these
apolipoproteins and lipoproteins with increased fatty acid
oxidation[52,53,57].Itwillbeofsigniﬁcancetodetermineif
selective fatty acids and fatty acid transport proteins regulate
the expression of PPARγ,L X R α, and SREBP-1c in hepatic
steatosis. Recently, the suppression of FATP3 (ACSVL3) was
shown to signiﬁcantly decrease the expression of lipogenic
transcription factors, PPARγ, ChREBP, LXRα, and SREBP1c
and their respective target genes, resulting in decreased de
novo lipogenesis (DNL) [46]. In hepatic steatosis, many of
the fatty acid transporter proteins are upregulated, yet it is
uncertain how this common event of increased hepatic fatty
acid levels seen in fasting leads to increased fatty liver and
lipotoxicity in the progression of NAFLD to NASH.
4. FattyAcid-Induced Lipotoxicity
Elevated intracellular fatty acids in hepatocytes lead to
lipotoxicity characterized by increased oxidative-stress and
lipid peroxidation, thus promoting the progression of simple
hepatic steatosis to steatohepatitis. Normal cellular fatty acid
homeostasis represents a balance between fatty acid uptake,
utilization, and export from the liver, which is controlled by
an elaborate transcriptional network that is ﬁnely tuned to
meet the energy needs of cells to prevent the accumulation
of fatty acids and toxic intermediates. However, when
this system is overwhelmed by excessive free fatty acids
(FFAs), hepatic steatosis commonly referred as NAFLD can
progress to steatohepatitis often referred as NASH. NASH is
characterized by cellular damage, inﬂammation, and varying
degreesofﬁbrosis[58].UntreatedNASHcanprogresstoliver
ﬁbrosis, contributing to hepatorenal portal hypertension,
liver cirrhosis, hepatic encephalopathy, and liver failure or6 PPAR Research
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Figure 1: Schematic diagram of the role of saturated fatty acids in causing nonalcoholic fatty liver diseases and lipotoxicity. The positive
signs with solid lines represent activation and/or upregulation of the downstream targets while the negative signs with broken lines indicate
the opposite eﬀects. Abbreviations used are HNF4α, hepatocyte nuclear factor 4; PPARα, peroxisome proliferator activator receptor α;A O X ,
acyl-CoA oxidase; CYP4A, cytochrome P450 4A; Scd-1, stearoyl-CoA desaturase.
progress to hepatocellular carcinoma [59, 60]. In the liver,
FFAs are considered the causative agents for hepatic steatosis
and also for obesity, and diabetes. Therefore, elucidating
the mechanism by which excessive hepatic FFAs induce
hepatic insulin resistance, hepatic gluconeogenesis, and fatty
acid disposal or intracellular partitioning is critical for
understanding the progression of steatosis to steatohepatitis.
Serum FFAs levels are increased in obese individuals in both
the fed and fasting states and have been shown to play a criti-
cal role in the progression of obesity to Type II diabetes [61].
FFAs in the liver desensitize insulin signaling by dampening
suppressionofhepaticgluconeogenesisthroughactivationof
p38 mitogen-activated kinase [62]. FFAs increase the tran-
scription of phosphoenolpyruvate carboxykinase (PEPCK),
glucose 6-phosphatase (G6Pase), peroxisome proliferator-
activated receptor coactivator α (PGC-1α), and cAMP-
responsive element binding protein (CREBP). Activation
of p38 kinase by FFAs is mediated by upstream activation
of protein kinase Cδ (PKCδ), which might be activated
by ACSLV-directed FFA diversion to diacylglycerol (DAG),
which is known to activate PKCδ in the presence of calcium.
Hepatic insulin resistance represents a paradox in hep-
atic steatosis since insulin receptor activation of insulin
receptor substrate-1 (IRS-1) is active and accounts for
increased DNL, yet insulin does not inhibit insulin receptor
substrate-2, which controls liver gluconeogenesis [63]. Both
IRS-1 and IRS-2 inhibit the transcription factor FOXO-
mediatedgenetranscriptionofPEPCK,G6Pase,andPGC-1α
[64]. Increased activation of IRS-1 during hyperinsulinemia
increases expression of SREBP-1c, which normally blocks
IRS-2 expression and CREBP critical for hepatic gluconeo-
genesis. Excessive FFAs induce hepatic insulin resistance
by activation of c-Jun N-terminal protein kinase (JNK),
which is known to be activated by oxidative stress and
cytokines, and is abnormally elevated in the diabetics [7,
65]. Thus, inhibition of JNK dramatically improves insulin
resistance and markedly decreases blood glucose levels. JNK
adenovirus overexpression increases serine phosphorylation
of IRS-1 with decreased IRS-1 tyrosine phosphorylation and
increased SREBP-1c activation, resulting in increased fat
synthesis and storage. JNK-mediated decreased activation
of IRS-1 also results in reduced suppression of FOXO1,
leading to increased hepatic gluconeogenesis. However, a
recent study reported that speciﬁc ablation of JNK1 in
hepatocytes exhibits glucose intolerance, insulin resistance,
and hepatic steatosis [66]. This study suggests that JNK1 has
opposing actions in liver and adipose tissue to promote and
preventhepaticsteatosis.LiverspeciﬁcJnk1-nullmicedisplay
increased gluconeogenesis and lipogenesis and, therefore,
have the paradox of selective insulin resistance that is a
central characteristic of type 2 diabetes. JNK activation has
also been implicated in FFA-induced hepatocyte lipoapop-
tosis by activation of proapoptotic BCL-2 proteins Bim and
Bax, triggering the mitochondrial apoptotic pathway [4,
67]. Furthermore, IRS-2 signaling was repressed in hepatic
insulin resistance by short-term feeding of FFAs, which
caused a 3-fold increase in triglycerides and acyl-CoAs. Not
only was tyrosine phosphorylation of IRS-2 decreased, but
also IRS-1 activation was suppressed in mice fed a high fat
diet. Consequently, the reduced tyrosine phosphorylation of
IRS-1 and IRS-2 in rat hepatoma cells exposed to palmitic
acid can be reversed by inhibition of acyl-CoA synthesis
of palmitoyl-CoA, suggesting an important role of FATP
(ACSLV) proteins in insulin signaling [50].
Although liver insulin resistance and hepatocyte apopto-
sisareinducedbyexcessiveFFAs,thequestionofwhichtypesPPAR Research 7
of fatty acids promote each process has not been explored in
mousemodelsofhepaticsteatosis.Recentdatasuggestedthat
partitioning of saturated and unsaturated fatty acids through
stearoyl CoA desaturase (SCD-1) determines the degree of
fatty acid induced liver injury [68]. SCD-1 knockout mice
areresistanttohepaticsteatosisandhepaticinsulinresistance
[69, 70]. SCD-1 regulates partitioning of saturated fatty
acids (SFAs) between MUFAs present in simple hepatic
steatosis and SFAs present during hepatic steatohepatitis
and ﬁbrotic livers. In an elegant study, Feldstein and col-
leagues clearly showed that MUFA leads to hepatic steatosis
without hepatocyte injury while SFA signiﬁcantly decreases
hepatocyte cell viability through caspase activation and
apoptosis [71]. Furthermore, inhibition of SCD-1 sensitized
hepatocytes to SFA-induced apoptosis, and mice fed with
a high-fat diet showed increased SCD-1 expression and
hepatic accumulation of MUFA. In contrast, mice fed with
a methionine-choline deﬁcient (MCD) diet that induces
steatohepatitis had increased hepatic levels of SFAs. Scd1-
null mice fed with the MCD diet showed decreased hepatic
steatosis, but increased apoptosis and liver ﬁbrosis, which
could be prevented by feeding MUFA. Therefore, although
Scd1-null mice are resistant to hepatic steatosis, they are
more susceptible to liver injury while increased SCD-1
expression during NAFLD reﬂects a compensatory beneﬁcial
eﬀect on increasing MUFA synthesis and storage of excessive
FFAs as triglycerides. Therefore, a decreased fatty acid
desaturation index (MUFA/SFA) may be one important
trigger in the progression of NAFLD to NASH. In addition,
a recent report revealed that the SFA C12:0 is a potent Toll-
like receptor four (TLR4) activator [72]. Toll-like receptors
are pattern-recognition receptors that induce the innate
and adaptive immune responses in mammals, and therefore
their activation by SFAs may initiate steatohepatitis. It is
interesting that PUFAs inhibit TLR4 dimerization, which
promotes the production of NADPH oxidase-dependent
ROS,whichisbelievedtobethesecondhitintheprogression
of steatosis to steatohepatitis.
5. MitochondrialFatty Acid Oxidationin
Hepatic Steatosis
In hepatic steatosis it is believed that mitochondrial dysfunc-
tion and decreased fatty acid β-oxidation are precipitating
causes for increased intracellular FFA accumulation and
hepatic insulin resistance. It is of interest that mitochon-
drial β-oxidation is active in patients with NAFLD, and
therefore the question of whether excessive inﬂux of FFAs
and overproduction of ROS promote mitochondrial injury
or simply represent the consequences of abnormal fatty
acid metabolism needs further investigation. Mitochondrial
β-oxidation is primarily responsible for the oxidation of
short chain (SCFA < C8), medium chain (MCFA, C8–C12),
and long chain (LCFA, C12–C18) fatty acids to acetyl-CoA,
which can be condensed into ketone bodies, oxidized to
CO2 and water, or serve as the building block for lipid
synthesis. Mitochondrial β-oxiation is regulated by carnitine
palmitoyltransferase (CPT1), carnitine concentration, and
malonyl-CoA produced by acetyl CoA carboxylase (ACC2)
from cytosolic acetyl-CoA. ACC2 gene expression is induced
by SREBP-1a, and therefore Srebp-1a- n u l lm i c eh a v el o w e r
hepatic levels of triglycerides and higher serum levels of
ketone bodies. SREBP-1a levels are increased in patients
with NAFLD and may provide an important mechanism
to prevent eﬃcient β-oxidation of fatty acids by increased
ACC2-mediated production of malonyl-CoA and inhibition
of CPT1. ACC2 knockout mice have a greater fatty acid
oxidation rate, with reduced fat mass and enhanced insulin
sensitivity[73].Theinitialstepinmitochondrialβ-oxidation
is the dehydrogenation of acyl-CoA esters by a family of
4 chain length speciﬁc straight chain acyl-CoA dehydro-
genases. Mice with disrupted MCFA or LCFA acyl-CoA
dehydrogenase develop micro- and macrovascular hepatic
steatosis [74]. In human with defects in mitochondria
trifunctional protein complex (MTPr), consisting of 2-enoyl
CoA hydratase, 3-hydroxyacyl-CoA dehydrogenase, and 3-
ketoacyl CoA thiolase activities, hepatic steatosis develops
quickly after birth, leading to premature death [75].
How lipotoxicity causes oxidative stress and mitochon-
dria dysfunction is an active area of research with regards
to palmitic acid toxicity. It is known that C16:0 is a poor
substrate for diacylglycerol acyltransferase, the last step in
TAGsynthesis;therefore,C16:0 isusedinsteadinthesynthesis
of ceramide, which can induce NADPH oxidase and disrupt
mitochondrial respiration either by inducing mitochondrial
release of cytochrome c or by disruption of the respiratory
chain complex III [76]. However, DAG through activation
of protein kinase C-dependent pathways is also able to
activateNADPHoxidaseandinitiateFFA-inducedapoptosis.
However, it is uncertain whether oxidative stress from
NADPH oxidase, cytochrome P450, or the mitochondria is
the main contributing factor in the progression of steatosis
to steatohepatitis. Treating rat H4IIEC3 hepatoma cells with
either C18:1 MUFA or C16:0 SFA revealed that palmitic acid,
but not oleate, inhibited IRS-2 tyrosine phosphorylation
and serine phosphorylation of AKT, through JNK activated
by mitochondria-derived ROS [77]. Thus, mitochondria-
derived ROS induced by palmitic acid may be a major
contributor to JNK activation and hepatic insulin resistance.
However, whether a similar mechanism occurs in animal
fed with a high-fat saturated fatty acid diet will have to
be determined. Indeed, mitochondria isolated from mice
fed a high fat diet show depressed state-3 respiration,
decreased uncoupled respiration, and decreased cytochrome
c oxidase activity with no change in complex-I-mediated
ROS production [78]. A reduced membrane potential of
mitochondria from mice fed with a high fat diet suggests that
mitochondria maynotbethemajorsourceofROSinhepatic
steatosis, which is contradictory to the results observed
with cultured hepatoma cells [77]. Unlike animal studies,
in humans with NAFLD, whole body lipid oxidation is
increased because of peripheral insulin resistance, suggesting
that impairment in hepatic fatty acid oxidation does not
seem to contribute to hepatic steatosis in humans [79],
although these data need further conﬁrmation. Therefore,
the role of mitochondrial fatty acid oxidation in the liver
seems controversial, with fatty acid oxidation viewed as a8 PPAR Research
protective mechanism of disposal of potentially toxic FFAs,
although increased oxidation of fatty acids can generate
ROS, which may initiate steatohepatitis. Fatty acids impair
mitochondrial function in human primary hepatocytes
through disruption of the respiratory chain activity. This
may increase ROS production in NAFLD patients, with
increased fatty acid β-oxidation, resulting in uncoupling of
the electron transport to oxidative phosphorylation [3, 80].
In addition to functional abnormalities in both experimental
models of hepatic steatosis and in human patients with
NAFLD/NASH, mitochondrial morphological changes have
been observed in steatohepatitis but not steatosis. These
morphological changes are believed to be due to oxidative
stress-induced phospholipid phase transition that is seen as
crystallinemitochondria inclusions [81]. Thus,the upstream
events that lead to mitochondrial dysfunction and whether
mitochondria are the source of ROS in NAFLD/NASH are
largely unknown. Indeed moderate mitochondrial dysfunc-
tion in the respiratory chains may be of beneﬁt in protecting
against obesity and diabetes, by inducing the expression of
mitochondrial uncoupling proteins (UCPs) and dissipation
of mitochondria membrane potential.
Mitochondrial uncoupling proteins (UCP2 and UCP3)
are believed to function to increase mitochondrial con-
ductance when activated by ROS. UCP gene expression
is increased in hepatic steatosis and evidence supports a
role for UCP3 in fatty acid metabolism by exporting fatty
acid anions, and thus maintaining mitochondria CoA levels
[82]. UCP3 was found to be necessary for fasting-induced
increase in fatty acid oxidation rate and capacity through
mitigation of mitochondrial oxidative stress [30]. When
there is an excess of FFA, either through passive transport
of shorter chain fatty acids from peroxisomes or ACSVL
activationandCPT1transportthatexceedthemitochondrial
fatty acid oxidation potential, there is a greater risk of
mitochondrial lipid peroxidation, which can be prevented
by UCP3-mediated eﬄux of fatty acids [83, 84]. Thus, the
increase in ACSLV and UCP3 proteins in hepatic steatosis is
an adaptive protective mechanism to prevent mitochondrial
lipotoxicity [85].
6. PeroxisomalFattyAcid Oxidationin
Hepatic Steatosis
The peroxisomal β-oxidation system metabolizes very long-
chain saturated and unsaturated fatty acids (VLCFA, >C18),
prostaglandins, and leukotrienes. Peroxisomes also metabo-
lize branched-chain fatty acids, dicarboxylic acid produced
by the microsomal ω-oxidation, and C27 bile acid interme-
diates. Unlike mitochondrial β-oxidation, peroxisomal β-
oxidation does not completely oxidize FAs to CO2 and water
but rather chain shortens FAs by 2 or 3 cycles of the β-
oxidation. The peroxisomal β-oxidation consists of a PPARα
inducible system that metabolizes straight-chain saturated
fatty acids and a noninducible pathway that metabolizes
branched-chain fatty acids and bile acid intermediates. The
initial oxidation of VLCFA is performed by the PPARα
inducible acyl-CoA oxidase (AOX1) producing trans-enoyl-
CoA, which is sequentially hydrated and dehydrogenated to
3-ketoacyl-CoA by a single bifunctional enzyme, L-enoyl-
CoAhydratase/L-3-hydroxyacyl-CoAdehydrogenase(L-BP).
The ketoacyl-CoAs are converted to acyl-CoAs and acetyl-
CoAs that are acted upon by a group of thioesterases, some
induced by PPARα, to acetate and short- or medium- chain
fatty acids that are transported to mitochondria for their
complete oxidation to CO2 and water. Branched-chain fatty
acids are metabolized by a noninducible AOX and then
further metabolized by the D-bifunctional enzymes (D-
enoyl-CoA hydratase/D-3-hydroxyacyl CoA dehydrogenase)
to acyl-CoAs, which are cleaved by a speciﬁc thiolase known
as sterol carrier protein (SCP-X).
The increased expression of the PPARα-dependent per-
oxisomal β-oxidation pathway induced in hepatic steatosis
provides an alternative mechanism to remove excessive fatty
acids. Impairment of mitochondrial β-oxidation is suggested
to be an important mechanism of fatty acid induced liver
injury. Inhibition of mitochondrial β-oxidation can lead to
dicarboxylic aciduria [86]; therefore, induction of peroxi-
somal β-oxidation pathway provides an adaptive protective
role in reducing intracellular levels of dicarboxylic acids
that inhibit the mitochondrial function. The importance
of peroxisomal β-oxidation in hepatic steatosis is evident
in Aox1-null mice, which show high levels of VLCFA
in serum and serve hepatic steatosis, steatohepatitis, and
hepatocellular carcinoma [56]. In lean and fatty (fa/fa)
Zucker rats, obese rats showed a 50% reduction in complete
mitochondria oxidation and a 3-fold increase in incomplete
peroxisomal β-oxidation. The increased peroxisomal β-
oxidation in Zucker obese rats accounted for up to 25% of
the total mitochondrial β-oxidation by supplying shorter-
chain fatty acids to mitochondria for complete oxidation
[87]. Therefore, the peroxisomal oxidation of VLCFAs to
SCFAs by incomplete β-oxidation provides a mechanism
by which FAs can be imported into mitochondria directly
without activation to a CoA ester and import by CPT1. The
peroxisomes have two systems to uptake fatty acids, either
as FA-CoA esters by using ATP-binding cassette transports
or as free fatty acids. These systems provide a mechanism to
prevent lipotoxicity of FFAs in the cytosol.
However, even though the peroxisomes have the capacity
to supply shorter-chain fatty acids to the mitochondria
for complete oxidation and an eﬃcient system to remove
excessive cytosolic free fatty acids, the β-oxidation system
is able to generate ROS. The peroxisome-produced H2O2
accounts for 35% of the total cellular hydrogen peroxide
produced and 20% of the total oxygen consumption in
hepatocytes [88]. Although peroxisomes have numerous
oxidase enzymes that produce H2O2, they also have several
antioxidant enzymes to prevent ROS-mediated cell damage
[89]. However, the massive proliferation of peroxisomes
in rodents by hypolipidemia drugs and peroxisome pro-
liferator chemicals is a viable reason why rodents develop
hepatocarcinogenesis [56]. The central event in rodent
hepatocarcinogenesis induced by peroxisome proliferators is
theactivationofPPARαsincePparα-n ullmic ear er efract o ry
to peroxisome proliferation and hepatocarcinogenesis whenPPAR Research 9
fed the nongenotoxic peroxisome proliferator and PPARα
ligand, Wy14,643 [90]. The low levels of PPARα in human
liver may be a reason why humans are resistant to the hep-
atocarcinogenic eﬀects of peroxisome proliferator chemicals
despite the beneﬁcial eﬀects of lipid lowering hypolipidemic
drugs in the treatment of dyslipidemia.
Theapparentbeneﬁcialeﬀectofperoxisomalβ-oxidation
in hepatic steatosis is evident in Aox1-null mice that develop
severe microvesicular steatohepatitis [91, 92]. Similarly,
Ppara-null mice also develop steatohepatitis [93]. In both
mouse models, peroxisomal β-oxidation is severely compro-
mised, resulting in increased dicarboxylic acids that uncou-
ple mitochondrial electron transport and inhibits mitochon-
drial β-oxidation pathway. However, in the Aox1-null mice,
there a massive induction of CYP4A genes while Ppar α-null
mice do not show induction of CYP4A genes. It is unclear
about the beneﬁcial role of CYP4A since neither the amount
of ω-hydroxylated fatty acids nor intracellular level of
dicarboxylic acids was determined in these studies [91–93].
However,thisparadigmofseveresteatohepatitisinAox1-null
and Ppar α- n u l lm i c ew i t hr e d u c e dp e r o x i s o m a la n dm i t o -
chondrial β-oxidation is questioned in double knock-out
(DKO) mice for both genes, which develop only mild steato-
hepatitis [94]. These results suggest that the role of CYP4A
in promoting the severity of steatosis in livers with defective
peroxisomal β-oxidation is still unclear because of the lack of
PPARα-mediated induction of CYP4A in DKO mice.
7. Regulation of Drug Metabolizing
CytochromeP450 Enzymes inNAFLD
The induction of cytochrome P450 drug metabolizing
enzymes has been implicated as a source of ROS in the
perpetuation and progression of steatosis to steatohepatitis.
Microsomaloxidationoffattyacids,catalyzedbycytochrome
CYP2E1, CYP4A10, CYP4A12, and CYP4A14, which are
induced in mouse models of steatosis and steatohepatitis, is
a potent source of ROS through uncoupling of their catalytic
cycles. The production of ROS by cytochrome P450 catalytic
cycle is dependent on the redox potential and spin state of
the transition element iron of heme [95]. Cytochrome P450
normally functions as a monooxygenase but can work as an
oxidase releasing H2O2 into endoplasmic environment. The
P450 catalytic cycle can produce superoxide and peroxide
by uncoupling of the substrate metabolism with electron
transport [96]. ROS can also be produced by the P450
catalytic cycle by futile cycling and redox cycling (Fe+2/Fe+3)
withtheformerproducingfreeradicalsemiquinonesandthe
latterbyasimilarredoxcyclingobservedinthemitochondria
electron transport chain [97].
Theethanol-inducibleCYP2E1iselevatedinbothrodent
experimental models of steatosis and steatohepatitis and
human NAFLD patients, and in vivo levels of CYP2E1 acti-
vation correlate with the severity of liver damage, suggesting
that this P450 is one of the major microsomal contributors
of ROS-induced hepatic injury [6, 98]. CYP2E1 is unique
among P450s since it is loosely bound to ER membrane
and naturally present in the high spin Fe+3 state. Therefore
it can produce ROS even in the absence of its potentially
toxic substrates [99] while its iron is able to interact directly
with molecular oxygen [96]. The induction of CYP2E1
by many potentially toxic/carcinogenic substrates such as
ethanol, benzene, and haloalkanes and their metabolisms
promote ROS production [6]. Furthermore, the substrates
that are poorly metabolized by CYP2E1 such as fatty acids
lead to uncoupling and futile catalytic cycle with increased
ROS production. Thus, the P450 catalytic cycle generates
signiﬁcant amounts of reactive superoxide anion, substrate
radical, and protonation of peroxy-cytochromes along with
a third leaky mechanism requiring two-electron transfer
followed by decay of peroxycytochrome P450 with the
release of superoxide. The eﬃciency of electron transfer
from NADPH to P450 catalytic cycle is called the degree
of coupling, which is less than 50% or lower in eukaryotes
[96]. Due to the high uncoupling rates of the P450 catalytic
cycle, the rates of NADPH and oxygen consumption are
weakly dependent on the presence of a substrate. Therefore,
the microsomal P450 monooxygenase system is a signiﬁcant
contributor of ROS formation in hepatocytes.
CYP2E1 seems to play a key role in the pathogenesis
of alcoholic liver injury because of its induction in chronic
alcohol drinkers and ability to produce ROS [100]. Increased
CYP2E1 protein levels are observed in animal models of
fatty liver diseases and in morbid obese men with NAFLD
and patients with NASH [101, 102]. CYP2E1 P450 levels
are increased in patients with NASH because fatty acids
and ketone bodies including acetone, which increased in
diabetes/ketosis [96], are substrates and inducers of CYP2E1
protein. However, even with this apparently close association
of CYP2E1 with both NAFLD and NASH and in several
animal models of both alcoholic and nonalcoholic steato-
sis, Cyp2e1-null mice still develop diet-induced NASH or
alcoholic liver inﬂammatory disease indicating that Cyp2e1
deletion neither prevented nor decreased oxidative damage
[103–105]. However, these Cyp2e1-null mice did show a
dramatic increase in the amounts of CYP4A10 and CYP4A14
fatty acid omega hydroxylases, and inhibition of CYP4A14
P450 prevented oxidative damage in Cyp2e1-null mice [104],
thus demonstrating an important role of CYP4A P450
isozymes in the steatohepatitis induced by a MCD diet.
The omegafattyacidhydroxylase P450s (CYP4A)metab-
olize a variety of endogenous saturated and unsaturated
fatty acids that are sequentially dehydrogenated to their
corresponding dicarboxylic acids in the cytosol [106]. Dicar-
boxylic acids are activated by dicarboxyl CoA synthetase
(ACSVL1) CoA esters that are chain shortened by peroxiso-
mal β-oxidation. Although microsomal ω-oxidation of fatty
acids and peroxisomal β-oxidation are minor pathways for
fatty acid oxidation, under fatty acid overload, signiﬁcant
amounts of dicarboxylic acids are formed in patients with
NAFLD, obesity, and diabetes. Dicarboxylic acids are highly
toxic to mitochondria and therefore eﬃcient disposal is nec-
essary to prevent mitochondrial dysfunction during hepatic
steatosis. PPARα agonists and fatty acids elevated during
fasting and hepatic steatosis could prevent dicarboxylic acid
formation through induction of the genes including ω-
oxidation CYP4A and peroxisomal β-oxidation.10 PPAR Research
Although the ethanol-inducible CYP2E1 and fatty acid
metabolizing CYP4A P450s may be directly involved in the
progression of steatosis to steatohepatitis by production of
ROS and initiation of lipotoxicity, other drug metabolizing
cytochrome P450 genes are dramatically aﬀected in fatty
liver disease and therefore have an important role in
identiﬁcation of appropriate drug treatment modalities to
avoid the consequences of adverse drug reactions or drug
toxicity. In primary human hepatocytes isolated from liver
with macrosteatosis, there is a 60% to 40% reduction in 7-
ethoxycoumarin O-deethylation (ECOD) and testosterone
oxidation with a reduction in CYP1A2, CYP2C9, CYP2E1,
and CYP3A4 mRNA and their respective proteins to metab-
olize their speciﬁc substrate drugs [107]. A recent study
analyzed changes in hepatic cytochrome P450 mRNA, pro-
tein and enzymatic activity in human patients with steatosis,
steatohepatitis and hepatitis without steatosis, which reﬂects
the beginning of liver ﬁbrosis [108]. These livers therefore
represent the progressive stages of NAFLD to NASH and
ultimately ﬁbrosis. During NAFLD progression, CYP2E1,
CYP2C19, and CYP1A2 mRNA and the corresponding P450
protein contents were decreased while those of CYP2A6,
CYP2B6 andCYP2C9mRNAandtheproteinswereincreased
[109]. During disease progression, CYP2D6, CYP3A4 or
CYP2C8 mRNA levels did not change; however CYP3A4 and
CYP2D6 protein levels decreased. The changes in CYP P450
levels correlated with the changes in the enzymatic activities
of the diﬀerent P450s in the progression of NAFLD. The
diﬀerential expression of P450 in the progression of NAFLD
to NASH and/or ﬁbrosis has an important clinical implica-
tion in patient treatment to avoid adverse drug reactions and
possible drug toxicity. CYP2C9 is the second most abundant
P450 expressed in human liver and is responsible for the
metabolism of S-warfarin, Tamoxifen, ﬂuoxetine, losartan,
and the antidiabetic PPARγ agonist rosiglitazone. The
increase in CYP2C9 mRNA, protein, and enzymatic activity
during NAFLD progression would suggest that the standard
dose of rosiglitazone to treat patients with type II diabetes
may be ineﬀective in managing hyperglycemia in patients
with NASH or liver ﬁbrosis. CYP3A4 is the most prominent
P450 expressed in the human liver and metabolizes over
50% of all therapeutic drugs prescribed. Therefore, reduced
CYP3A4 levels during the progression of NAFLD to ﬁbrosis
and liver cirrhosis put these patients at risk for adverse drug
reaction and possible drug toxicity [110]. In contrast to the
many studies indicating a role of CYP2E1 in NAFLD and
NASH [109], the decrease in CYP2E1 mRNA and protein
from steatosis to steatohepatitis and ﬁbrosis needs to be con-
ﬁrmed independently. However, these data question the role
of CYP2E1 in oxidative damage-induced disease progression
and suggest a possibility that other P450 enzymes such as
CYP4A isozymes elevated in NAFLD and NASH may be
involved in the progression of fatty liver diseases.
8. Microsomal FattyAcid Oxidation in
Hepatic Steatosis
Theω-hydroxylationofsaturatedandunsaturatedfattyacids
by CYP4 family members has long been thought to be a
minor pathway in the metabolism of fatty acids account-
ing for 5%–10%. However, its importance is dramatically
increased due to their upregulation during fasting, starva-
tion, and in several human diseases where its contribution
to fatty acid metabolism increases dramatically to 15%–
30%. The close association between microsomal CYP4 ω-
hydroxylation of MCFAs and peroxisomal β-oxidation of
LCFAs is evident by the conversion of dicaboxylic acids
to succinate, an anaplerotic gluconeogenic precursor, and
acetate, which can be used by peripheral tissue like ketone
bodies during fasting and starvation through a dramatic
induction of CYP4A genes. The increased expression of
CYP4A genes during fasting, starvation, by a high fat diet
and in steatohepatitis may be a mechanism to prevent
lipotoxicity from FFAs, but at the expense of possibly
increased uncoupling of the P450 catalytic cycle, leading to
increased ROS production.
In mammals, six CYP4 gene subfamilies have been iden-
tiﬁed: CYP4A, CYP4B, CYP4F, CYP4V, CYP4X,a n dCYP4Z
[111–114]. Three of these subfamily members (i.e., CYP4A,
CYP4B,andCYP4F)havebeenshowntoω-hydroxylatesatu-
rated, branched, unsaturated fatty acids and the eicosanoids.
Members of the CYP4B subfamily metabolize SCFAs (C7–
C9), while members of the CYP4A subfamily metabolize
MCFAs (C10–C16), and members of the CYP4F subfamily
metabolize LCFA and VLCFA (C18–C26) fatty acids.
Members of the CYP4A family are by far the best
characterized ω-fatty acid hydroxylases in regard to their
induction by peroxisome proliferators, PPARα, and regu-
lation by fasting, high fat diet, ethanol consumption, and
in diabetes in rodents. The importance of CYP4A P450s in
the metabolism of MCFAs is evident by their upregulation
during starvation, caloric restriction, and in animals fed a
high fat diet, which mimics starvation-induced lipolysis and
excessive fatty acid transport to the liver. In these situations,
there is a dramatic induction of the CYP4A genes, which may
function to not only prevent lipid toxicity but also provide
consumablenutrientsforperipheraltissueduringstarvation.
MCFAs in hepatocytes are transported into the peroxisomes
asFFAsorasdicarboxylicacidsafterCYP4Aω-hydroxylation
and esteriﬁed by peroxisomal acyl-CoA synthetase ACSVL1
(FATP2) and ACSVL5 (FATP4) [26]. MCFA acyl-CoAs
undergo 2 to 3 rounds of peroxisomal β-oxidation, produc-
ing succinyl-CoA and acetyl-CoA [115, 116]. These products
are converted by several peroxisomal acyl-CoA thioesterases
(ACOT), which can catalyze the hydrolysis of CoA esters
of diﬀerent chain-length fatty acids including succinate.
Succinate can be directly used as an anaplerotic intermediate
for gluconeogensis while released acetate can be taken up
and oxidized by extra-hepatic tissues in the same way as
ketone bodies for energy production. During starvation or
administration of hypolipidemic drugs that activate PPARα,
there is a rapid proliferation of peroxisomes in rodents but
not humans. In humans, the CYP4A11 and CYPF2 genes are
not induced by peroxisome proliferators (PP), and therefore
the absence of peroxisome proliferation may be due to
decreased levels of ωHEET, which is a high aﬃnity ligand in
the PPARα activation. In humans, the hypolipidemic eﬀect
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activation but through the suppression of HNF4α by PPs-
CoAs [55].HNF4αcontrolsgenesinvolvedintheproduction
of lipoproteins [55]. Thus, the activation of PPARα in
rodents by ωHEET and the suppression of HNF4α in
humans by PP-CoAs may explain the absence of peroxisome
proliferation in humans and why humans in contrast to
rodents are resistant to the hepatocarcinogenic eﬀects of
hypolipidemic drugs.
In contrast to the CYP4A members, CYP4F P450s
isozymes ω-hydroxylate a variety of LCFAs and VLCFAs,
unsaturated and branched-chain fatty acids,and vitamins
with long alkyl side chains, the physiologically impor-
tant leukotrienes (LT), prostaglandins (PG), and hydrox-
yeicosatetraenoic acids (HETE) [117–121]. The human
CYP4F P450s metabolize and inactivate the proinﬂam-
matory leukotriene B4 (LTB4)[ 118], with the myeloid-
expressed CYP4F3A having a twofold greater aﬃnity for
LTB4 than CYP4F2 expressed in liver, kidney, and skin,
but not in myeloid cells. However, CYP4F3B splice variant
of the CYP4F3 gene expressed in liver and has a similar
aﬃnity as CYP4F2 for LTB4 [122]. Both CYP4F3B and
CYP4F2 P450 can metabolize arachidonic acid to 20-HETE
while CYP4F3A has little activity towards arachidonic acid.
Besides ω-hydroxylating other proinﬂammatory eicosanoids
such as 5-HETE, 12-HETE, and 8-HETE, CYP4F P450s can
metabolize the anti-inﬂammatory lipoxins, LXA4,a n dL X B 4.
The ability of CYP4F3 and CYP4F2 to ω-hydroxylate both
pro- and anti-inﬂammatory leukotrienes indicates that they
may function both in the activation and resolution phases of
the inﬂammatory response [106, 113].
Similar to the MCFAs and SCFAs, omega-hydroxylated
LCFAs and VLCFAs are converted to their corresponding
dicarboxylicacidsbythesequentialactionofcytosolicalcohol
and aldehyde dehydrogenases. The roles of diﬀerent chain
length ω-hydroxylated fatty acids in lipid metabolism are
indicated by increased ω-hydroxylation of MCFAs by CYP4A
P450s in rodents during fasting, by peroxisome proliferators,
and in hepatic steatosis while decreased CYP4F genes
expressionbyperoxisomeproliferatorsandduringstarvation
results in reduced ω-hydroxylation of LCFAs and VLCFAs.
Unlike the ω-hydroxylated MCFAs, which are β-oxidized
to succinyl-CoA and acetate, the omega-hydroxylation of
LCFAs would produce only SCFAs and acetate. Excessive
acetate in the hepatocyte cytosol [123] can be used for the
synthesis of cholesterol and fatty acids with malonyl-CoA
inhibiting the mitochondrial CPT1 fatty acid uptake and
therefore blocking mitochondrial β-oxidation. Dicarboxylic
acids are almost elusively metabolized by the peroxisomal β-
oxidation system since the Km value for dicarboxylic acids
by the mitochondrial system is 15–40-fold higher than that
of the peroxisomes [124]. Furthermore, branched and long
chain saturated and unsaturated fatty acids are preferentially
metabolized by the peroxisomes. The transportation of fatty
acids into the peroxisomes is diﬀerent for MCFAs, LCFAs,
and VLCFAs. MCFAs are transported as free acids, which
are esteriﬁed in peroxisomes to their corresponding CoA
derivatives by FATP2 and FATP4, while LCFAs and VLCFAs
are transported by ABC transporters as CoA derivatives
[125]. In addition, β-oxidation in the peroxisomes does
not completely oxidizes fatty acid substrates but produces
shorter-chain fatty acids which are transported from the
peroxisomes to mitochondria for either complete oxidation
by the mitochondrial β-oxidation or usage for synthesis of
other fatty acids, as seen in the conversion of C24:6n-3 to
docosahexaenoic acid (C22:6n-3).
Omega-hydroxylated fatty acids and eicosanoids have
several metabolic fates dependent upon the cell type and
CYP4 genes expressed. In the liver, ω-hydroxylated fatty
acids can be metabolized and used for energy production,
lipogenesis, the synthesis of structural lipids, and production
of fatty acids that function as agonists in the regulation of
hormone nuclear receptors (HNRs) (Figure 1). The diverse
array of fatty acids omega-hydroxylated by members of the
CYP4 family and their functional roles in metabolism, cell
signaling, inﬂammation, and lipid structure suggest that
CYP4 members play an important role in human diseases
[106]. The importance of ω-hydroxylated fatty acids and
eicosanoids in human diseases is evident by the role 20-
HETE has in hypertension and vascular disease and its
dramatic appearance in patients with end stage liver diseases,
and the possible role of ω-hydroxylated fatty acids in lipid
metabolism in fatty liver diseases [113, 126–128].
9. Role of CYP4 Isozymes inthe Initiationand
Progressionof NAFLD to NASH
NAFLDencompassesabroaddisease spectrumrangingfrom
simple triglyceride accumulation in hepatocytes (hepatic
steatosis) to hepatic steatosis with inﬂammation (steatohep-
atitis) that can progress to ﬁbrosis and cirrhosis [1]. A two-
hit hypothesis has been proposed to explain the progression
of NAFLD as hepatic triglycerides being the ﬁrst hit, while
increased oxidative stress, as the second hit, promoting liver
inﬂammation, cell death, and ﬁbrosis in NASH [127, 129].
Both obesity and insulin resistance are strongly associated
with NAFLD, resulting in the hydrolysis of adipose triglyc-
erides by hormone sensitive lipases, leading to elevated
plasma and hepatic levels of FFAs. In the liver FFAs can be
either metabolized by the mitochondrial β-oxidation system
for energy production or esteriﬁed to triglycerides and
incorporated into VLDL particles with cholesterol esters and
phospholipids for transport and use by peripheral tissues.
Through the use of mouse models of fatty liver disease
and the generation of knockouts of key regulator enzymes
involved in lipid and glucose metabolism, we are beginning
to understand the key molecular targets responsible for
increased triglyceride accumulation in hepatocytes and how
fatty acids induce oxidative stress and the progression of
steatosis to steatohepatitis.
Key regulatory enzymes control the ability of the liver to
providenutrientstoperipheraltissuesthroughgluconeogen-
esis, ketogenesis, VLDL secretion and possibly acetate. Inter-
estingly, key regulatory enzymes are diﬀerentially aﬀected in
liver insulin resistance with the major pathway in lipogenesis
being activated while the hepatic gluconeogenic pathway is
active under insulin resistance. Both acetyl-CoA carboxylases
(ACC1 and ACC2) and stearoyl-CoA desaturase (SCD-1) are12 PPAR Research
activated in the insulin resistant liver. ACC1 is responsible
for converting acetyl-CoA to malonyl-CoA, which functions
as both a precursor of cholesterol and fatty acid synthesis
and also a potent inhibitor of mitochondrial CPT1 necessary
for the transport of fatty acids to the mitochondria for β-
oxidation while SCD-1 functions to desaturate stearic acid
(C18:0) to oleic acid (C18:1) necessary for synthesis of triglyc-
erides. These genes are activated through insulin-mediated
activation of two transcription factors (e.g., SREBP-1c and
ChREBP). During hepatic steatosis in both humans and
mouse models, there is an excessive accumulation of oleic
acid either from increased de novo fatty acid synthesis
or conversion of imported fatty acids from the adipose
tissues. Elevated hepatic glucose production in the presence
of hyperinsulinemia is a hallmark of insulin resistance in
the liver even with the increased expression of the liver
speciﬁc pyruvate kinase (L-PK), a key regulatory enzyme in
converting phosphoenolpyruvate to pyruvate during glycol-
ysis. Increase L-PK gene expression is mediated by glucose
activation of the ChREBP transcription factor. ChREBP
has also been shown to increase the expression of many
of the fatty acid synthesis enzymes as well as SCD-1,
thereby facilitating the conversion of glucose to fatty acids.
It is presently unknown why hyperinsulinemia activates the
lipogenic pathway, but fails to prevent the inactivation of
a gluconeogenic pathway and hyperglycemia observed in
insulin resistant diabetes [127, 129, 130].
The activation of both anabolic and catabolic pathways
during insulin resistance in the liver suggests that diﬀerent
fasting and feeding signals are simultaneously controlling
the metabolic responses of the liver. What these signals
are and how they function either directly to activate key
regulator enzymes or as agonists or antagonists to activate
key transcription factors that control the expression of the
genes involved in fatty acid catabolism (PPARα,H N F 4 α)o r
fatty acid synthesis (SREBP-1c, ChREBP, PPARγ)r e m a i nt o
be determined.
The increase in peroxisomal β-oxidation during steatosis
exerts a beneﬁcial eﬀect in NAFLD by metabolizing excessive
fatty acids to shorter-chain fatty acids that can be directly
transportedandcompletelyoxidizedbythemitochondrialβ-
oxidationsystem.Inaddition,theincompleteperoxisomalβ-
oxidation of fatty acids cansupply the anaplerotic mitochon-
drial intermediate, succinate, necessary for gluconeogenesis,
while acetate from acetyl-CoA can be used for the anabolic
synthesis of cholesterol and fatty acid as seen in NAFLD
[131–133]. The peroxisomes, unlike mitochondria, metabo-
lize long chain fatty acids, exclusively metabolize branched-
chain fatty acid, and preferentially metabolize dicarboxylic
acids, which are produced by the ω-hydroxylation of fatty
acids by members of the CYP4 gene family. The increased
expression of the CYP4A omega-hydroxylases during steato-
hepatitis and their induction in animals fed with a high-fat
diet suggest that they may play a pivotal role in lipotoxicity
[134], and may be responsible for the induction of oxidative
stress as well as progression to steatohepatitis. A dramatic
induction of both the mouse CYP4A10 and CYP4A14 genes
is seen in Cyp2e1-null mice and likely accounts for the
increased ROS that induce lipid peroxidation [103, 104]. The
increased production of dicarboxylic acids during steatosis
by CYP4A members can impair mitochondrial function
by dissipation of the mitochondria proton gradient and
uncoupling of oxidative phosphorylation. In addition, the
uncoupling of the P450 catalytic cycle has been known to
be a major source of ROS, which led to the identiﬁcation
of the ethanol-inducible CYP2E1 P450 as a major source of
ROS-mediated microsomal lipid peroxidation [96]. CYP2E1
can metabolize fatty acids at the ω-1 position, and CYP4A,
which normally ω-hydroxylates lauric acid and hydroxylates
longer chain fatty acids at both the ω-a n dω-1 positions. It is
not known whether diﬀerent chain length fatty acids assist in
the uncoupling of the CYP2E1 and CYP4A catalytic cycles
or whether cytochrome b5, which increases P450 catalytic
activity and prevents uncoupling, can reduce ROS formation
in fatty liver disease [135]. Both cytochrome b5 reductase
and cytochrome b5 are also used in the desaturation of
stearic and palmitic acids by SCD-1. It is unknown whether
increased conversion of stearic acid to oleic acid observed
in NAFLD increases uncoupling of the P450 catalytic cycle,
resulting in increased ROS formation by SCD-1 sequestering
cytochrome b5.B o t hc y t o c h r o m eb 5 and cytochrome b5
reductase have been identiﬁed as susceptibility genes in
obesity [136]. While the induction of CYP4A genes during
fasting provides both gluconeogenic precursors and acetate
to supply the needs for peripheral tissues, their induction
during steatosis may increase hyperglycemia, shuttle acetate
for synthesis of fatty acids and cholesterol, and increase ROS
formation by uncoupling of the P450 catalytic cycle.
Similar to the role of CYP4A genes in possibly initiating
hepatocyte cell injury and steatohepatitis, CYP4F genes may
also play a functional role in hepatic lipid accumulation
and in the recruitment of inﬂammatory cells during pro-
gression from steatosis to steatohepatitis. Unlike CYP4A
genes that are induced by fasting, hypolipidemic drugs,
and peroxisome proliferators through PPARα activation,
the CYP4F genes were reported to be repressed during
fasting and by peroxisome proliferators possibly by PP-
CoA or PUFA-CoA mediated inhibition of HNF4α [137].
Furthermore, unlike the CYP4A genes that are induced in
fatty liver, our preliminary data suggest that the mouse
CYP4F genes may be repressed in mice fed a high fat diet
and in the leptin-deﬁcient ob/ob mice as a model of fatty
liver disease (unpublished results). The recent report of
lipid accumulation in primitive liver cells (oenocytes) of
Drosophila that have a mutation in the stearic ω-hydroxylase
CYP4g1 gene [138] suggests that CYP4F genes may play
an important role in maintaining lipid homeostasis in the
liver. Drosophila homozygous mutant for CYP4g1 manifests
a two-fold increase in the oleic acid : stearic acid ratio
(C18 : 1/C18 : 0) with a notable imbalance in the fatty acid
desaturation found in the TAG fraction but not in the phos-
pholipid fraction. This suggests that CYP4g1 is important in
the metabolic storage of fatty acids and its expression would
decrease oleic acid synthesis and storage of fatty acids in
TAGs. The human CYP4F2 eﬃciently ω-hydroxylates stearic
acid and therefore may serve the same function as CYP4g1
in competing with SCD-1 in the metabolism of stearic acid
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gene is repressed by fatty acids in patients with NAFLD.
However, one study suggested that the human CYP4A11
mRNA was reduced in obese individuals [126]. In contrast,
the CYP4F2 gene has been shown to be downregulated by
peroxisome proliferators [139], induced by retinoic acids
[140], and its expression increased by lovastatin-mediated
activation of SREBP-2 [141].
Therefore,theactivationofthe CYP4F2geneinfattyliver
diseases may decrease the formation of oleic acid and storage
of TAG in the liver, and also play a vital role in preventing
recruitment of immune cells to the liver during steatohepati-
tis by metabolism of the proinﬂammatory leukotrienes. Even
though there are numerous studies showing that fatty acids
induce hepatocytes to produce proinﬂammatory cytokines
and chemokines (IL-8) which attract neutrophils to the
liver, the function of leukotrienes in attracting immune cells
to the liver during steatohepatitis has not been explored.
Whether LTB4 or LTC4 increases production of the potent
neutrophil chemokine IL-8 during hepatic steatosis remains
to be determined. The genetic association of CYP4F2 and the
neutrophil-speciﬁc CYP4F3A gene in Celiac disease estab-
lishes a connection between the innate immune response
of neutrophil recruitment to the established Th1 adaptive
immune response in disease patients [142]. Furthermore,
Celiac disease has been associated with several inﬂammatory
diseases of the liver including primary biliary cirrhosis,
primary sclerotizing cholangitis, autoimmune hepatitis,
hemochromatosis, and fatty liver diseases [143].
It will be of signiﬁcant importance to understand how
the CYP4F genes are regulated by fatty acids and in animal
models of fatty liver disease. Whether induction of CYP4F
long chain fatty acid ω-hydroxylases can prevent steatosis
by inhibiting SCD-1 activity and reduce the hepatic levels
of proinﬂammatory leukotrienes in steatohepatitis needs
further study.
10.GeneticRegulation of CYP4A andCYP4F
GenesandTheir Roles inLipidMetabolism
during Hepatic Steatosis
ThediﬀerentialregulationoftheCYP4AandCYP4F genesby
peroxisome proliferators, during fasting and by high fat diets
indicates that these P450s may have distinct roles in lipid
metabolism during the fasting and feeding cycles, and that
diﬀerentnucleartranscriptionfactorsregulatetheexpression
of these genes (Figure 1). It is well established that the rodent
CYP4A genes are induced by or during hepatic steatosis
and steatohepatitis [104, 134, 144, 145]. However, their
functional roles in initiation and progression of NAFLD to
NASH are relatively unknown. The importance of induction
of CYP4A genes in hepatic steatosis and steatohepatitis
was revealed in Cyp2e1-null mice that developed severe
steatohepatitis with a pronounced increase in CYP4A10 and
CYP4A14 associated with increased accumulation of lipid
peroxides. The knockout mice deﬁcient of the peroxisome
straight chain acyl-CoA oxidase (Aox-null) fed a normal
diet develop severe steatohepatitis with a massive increase in
CYP4A protein expression. In contrast, Pparα-null and Aox-
null double-knockout mice develop only mild to moderate
steatohepatitis with much less lipid peroxide accumulation
because a CYP4A protein, which produces ROS and lipid
peroxidation, was not induced. It is known that PPARα
agonists exhibit a beneﬁcial eﬀect on preventing steatohep-
atitis by increasing fatty acids β-oxidation and indirectly
by inhibiting SREBP-1c, thus protecting against obesity-
induced hepatic inﬂammation [146, 147]. To resolve this
issue, Leclercq and colleagues fed wild type and Pparα-
null mice with a MCD diet to induce steatohepatitis and
the speciﬁc PPARα agonist, Wy14,643 [145]. MCD-diet
fed Pparα-null mice, which are very sensitive to oxidative
stress [148], develop severe steatohepatitis in the absence of
CYP4A induction and, Wy14,643 decreased the degree of
steatohepatitis in these mice. These data suggest that CYP4A
induction was not necessary for promoting steatohepatitis or
the cause of increased microsomal lipid peroxides in Pparα-
null mice fed a MCD diet [145]. It is diﬃcult to reconcile the
eﬀect of the PPARα agonist in the prevention of steatohep-
atitis in Pparα-null mice since none of the mitochondrial,
peroxisomalβ-oxidation,andmicrosomalω-oxidationpath-
ways was induced by Wy14,643 in these mice. These results
indicate that inﬂammatory cells might be responsible for
increased lipid peroxidation and steatohepatitis in Pparα-
null mice. These data further suggests that Wy14,643 may
have a PPARα independent eﬀect on the amelioration of
steatohepatitis. In fact, another PPARα agonist bezaﬁbrate
at clinically relevant doses decreased serum and liver triglyc-
erides through down-regulation of SREBP-1c, revealing a
clue for PPARα-independent mechanism in the suppression
of de novo lipogenesis [146]. In contrast, wild-type mice fed
the MCD diet and Wy14,643 do not develop steatohepatitis,
although both the rates of peroxisomal and mitochondrial
β-oxidation are increased with a 20∼50-fold-fold upregu-
lation in CYP4A10 and CYP4A14 gene expression. Thus,
these results further question the role of ROS generation
from either mitochondrial β-oxidation or microsomal ω-
oxidation in the development of steatohepatitis. To resolve
this issue and to further deﬁne the role of CYP4A genes in
production of ROS during hepatic steatosis, mouse models
overexpressing CYP4A10 and CYP4A14 will be needed to
determine if excessive fatty acid induces uncoupling of the
P450 catalytic cycle and generation of ROS during the
progressionofNAFLDtoNASH.However,mostPPARαago-
nists activate the expression of the CYP4A genes, suggesting
an interesting paradox whether CYP4A gene induction is
beneﬁcial or harmful in promoting steatohepatitis. A recent
study suggests that CYP4A14 overexpression in hyperoxia
increases resistance to oxidative stress [149]. In contrast to
the extensive data on the role of rodent CYP4A gene in
animal models of steatosis and steatohepatitis, little is known
abouthowthehumanCYP4A11geneiscontrolledbyPPARα
agonists and its functional role in NAFLD or NASH. The
modest2-foldinductionoftheCYP4A11genebyperoxisome
proliferators in primary human hepatocytes compared with
the30–70foldinductionofthemouseCYP4Agenesindicates
as p e c i e sd i ﬀerence between rodents and humans with
respect to regulation of the CYP4A genes by peroxisome14 PPAR Research
proliferators [150]. In addition, the 60–700 fold increase in
mouse CYP4A mRNA during fasting [144] and 2–8 fold
decrease in CYP4F mRNA further indicate the diﬀerential
regulation of these distinct genes. In humans with obesity,
CYP4A11mRNAdecreasedby50% whileinNAFLDpatients
while CYP4A11 mRNA increases 4-fold [126], suggesting a
diﬀerential regulation in liver disease progression.
LCFAsareendogenousligandsintheactivationofNHRs,
PPARα and HNF4α. LCFAs and LCFA-CoAs are signiﬁcant
NHR ligands as shown by their presence in the nucleus,
their high aﬃnity binding (Kd values ∼ nM ranges), their
ability to induce conformational changes in NHRs, and
their ability to induce coregulator recruitment to nuclear
receptors [55]. Support for LCFA-CoAs in the hyperactiva-
tion of PPARα was evident in Aox-null mice with accumu-
lated VLCFAs and VLCFA-CoAs, and the observation that
the thio-esteriﬁcation inhibitor, 2-bromopalmitate inhibits
bezaﬁbrate induced peroxisome proliferation in rodents.
In humans, the importance of VLCFA-CoAs in PPARα
activation was evident in adrenoleukodystrophy where there
is accumulation of VLCFA in the cytosol, but no peroxisome
formation of VLCFA-CoA and no hyperactivation of PPARα
[120]. Serum fatty acids increase dramatically from the
normal physiological range of 200uM to 1mM under fasting
and up to 8mM in Refsum’s disease, adrenoleukodystrophy,
Zellweger’s syndrome, and fatty liver diseases, diabetes, and
inﬂammation. This suggests an important link between
peroxisomefattyacidmetabolismandconversionofVLCFAs
to VLCFA-CoAs in the activation of PPARα and control of
CYP4 gene expression. PPARα has a high aﬃnity for polyun-
saturated LCFAs, LCFA-CoAs and VLCFA-CoAs, but not
saturated LCFAs or VLCFAs while HNF4α has a high aﬃnity
for saturated LCFAs and VLCFA acyl-CoAs but not polyun-
saturatedacyl-CoAs(Figure 1).Thesefactsindicatethatfatty
acid CoA chain length and degree of unsaturation determine
whether HNF4α or PPARα will be activated [48]. The mech-
anism of LCFA uptake and importation into the nucleus
has recently been shown to be mediated by L-FABP, which
binds polyunsaturated LCFAs with a greater aﬃnity than
saturated LCFAs and associates with PPARα, while ACBP
preferentially binds saturated LCFAs and associates with
HNF4α [55]. These studies indicate that ACBP selectively
cooperates with HNF4α while L-FABP selectively cooperates
with PPARα, which is believed to elicit downstream alter-
ation in coactivator and corepressor association with NHRs.
Thus, the binding of saturated LCFA-CoAs to HNF4α would
increase HNF4α activity and inhibit PPARα transactivation
while polyunsaturated LCFA-CoAs would decrease HNF4α
activationandincreaseL-FABPPPARαtransactivation.Since
PPARα and HNF4α regulate gene transcription through
similar promiscuous DR1 sequences, and compete for the
samecoactivatorsandcorepressors,thespeciﬁcityofreceptor
activation may be determined by either saturated or polyun-
saturated fatty acid ligand while the cross-talk between
these transcription factors would be determined by the
FABP/ACBP mediated coregulator recruitment and repres-
sionofthecognatereceptor.Forinstance,thediﬀerentialreg-
ulation of the CYP4A and CYP4F genes may be determined
by cross-talk between PPARα and HNFα through the type
of fatty acid ligand, method of nuclear import, and receptor
activation by L-FABP or ACBP. This scenario is highly
likely in the regulation of CYP4A and CYP4F genes since
peroxisome proliferators (PP) activate PPARα while PP-
CoAs inhibits HNF4α transactivation. It is also possible that
MCFAs and VLCFAs metabolized by the CYP4A and CYP4F
may produce fatty acid metabolites that reciprocally regulate
the expression of the CYP4A and CYP4F genes (Figure 1).
The induction of CYP4A genes by a high fat diet leads to
increased production of dicarboxylic acids that are potent
inhibitors of HNF4α transactivation, which may contribute
to the suppression of the CYP4F genes during steatosis.
11. Conclusion and Discussion
The concentrations of FFAs increase either in the blood
plasma through a high-fat diet and release by adipocytes or
in the liver as a consequence of lipolysis or de novo fatty
acid synthesis. FFAs travel through the body mainly bound
to albumin and intracelluarly bound to fatty acid transport
proteins (FABP, FATP), which regulate their intracellular
fate. Evidence suggests that FFAs induce insulin resistance by
raising intracellular lipid metabolites, which activate protein
kinase C that inhibits nuclear factor kappa β kinase and
activates the inﬂammatory pathway. Activation JNK and/or
p38 kinase especially by saturated FFAs and increased ROS
[151, 152] leads to serine phosphorylation and inhibition
of insulin receptor substrates IRS-1 and IRS-2, resulting in
decreased insulin signaling (i.e., decreased Tyrosine phos-
phorylation) and increased hepatic gluconeogenesis during
insulin resistance. The elevation of plasma FFAs in obesity,
fatty liver diseases and insulin resistance are predictors of
type 2 diabetes, and therefore understanding the mecha-
nisms to decrease hepatocyte intracellular levels of FFAs will
oﬀer opportunities to prevent hepatic lipotoxicity and treat
not only fatty liver diseases, but also metabolic syndrome
associated with obesity and diabetes. The importance of
understanding the mechanism by which PPARs can be
used to treat hepatic steatosis is apparent considering that
PPARα, although downregulated in fatty liver diseases, is a
viable target to increase the mitochondrial, peroxisomal β-
oxidation, and microsomal ω-oxidation of FFAs to prevent
lipotoxicitydespiteproductionofsomeROSbythelattertwo
processes. In hepatic steatosis and NAFLD, hepatic PPARγ
levels increase; this compensates for the decreased PPARα
and presents another important target to prevent excessive
intracellular FFAs by increasing de novo lipogenesis and
thus preventing the lipotoxicity from FFAs. It will be of
importance to determine if PPARγ is able to be activated
by selective fatty acids through interaction with L-FABP
or ACBP. Furthermore, recent evidence has suggested that
PPARδ is a true sensor of plasma FFA levels by interacting
with and stimulating the expression of lpin2 and St3gal5
genes after fasting [153]. Whether selective activation of
PPARδ can activate the genes involved in either the disposal
or lipogenesis to prevent FFA-mediated lipotoxicity will be
important in understanding the pathogenesis of NAFLD
and NASH. Although, steatosis is the ﬁrst step or hit inPPAR Research 15
the progression of NAFLD to NASH, the source of ROS
in the second step has not been clearly deﬁned and will
requireinvestigations.Thesemayincludesimultaneousmea-
surement of the source of ROS generated by mitochondria,
peroxisome, microsome, and inﬂammatory cells during the
progression of steatosis to steatohepatitis. Finally, based on
the similar steps of disease progress between NAFLD and
alcoholic fatty liver diseases (AFLD) [7, 152], the similar
mechanisms and relevant problems can be also applied to
understanding of the pathogenesis mechanisms of AFLD.
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